Trial NCT02900560

View at ClinicalTrials.gov 
Org. Study IDs: TRIO026

Last trial update was posted on 2022-06-10

MeSH Interventions

Azacitidine Cc-486 Pembrolizumab

MeSH Conditions

Carcinoma, Ovarian Epithelial Ovarian Neoplasms

Other Conditions

Epithelial Ovarian Cancer

Stopping Reasons

N/A

Limitations And Caveats

Trial closed prematurely with 34 participant enrolled in Part A of the study. All of the treatment cohorts met at least one of the safety rejection criteria. Enrollment took 31 months, significantly longer than anticipated (24 months).

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID